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Background: The aim of this study was to review the current status and usage of guidelines in the diagnosis and
treatment of community-acquired pneumonia (CAP) in European countries and to compare to established
guidelines in the United States (US), United Kingdom (UK), and the World Health Organization (WHO).
Methods: A questionnaire was developed and distributed by the Community-Acquired Pneumonia Paediatric
Research Initiative (CAP-PRI) working group and distributed to medical centres across Europe.
Results: Out of 19 European centres, 6 (31.6 %) used WHO guidelines (3 in combination with other
guidelines), 5 (26.3 %) used national guidelines, and 5 (26.3 %) used local guidelines. Chest radiograph and
complete blood count were the most common diagnostic examinations, while evaluation of clinical
symptoms and laboratory tests varied significantly. Tachypnoea and chest recession were considered criteria
for diagnosis in all three guidelines. In US and UK guidelines blood cultures, atypical bacterial and viral
detection tests were recommended. In European centres in outpatient settings, amoxicillin was used in 16
(84 %) centers, clarithromycin in 9 (37 %) centers and azithromycin in 7 (47 %) centers, whereas in hospital
settings antibiotic treatment varied widely. Amoxicillin is recommended as the first drug of choice for
outpatient treatment in all guidelines.
Conclusions: Although local variations in clinical criteria, laboratory tests, and antibiotic resistance rates may
necessitate some differences in standard empirical antibiotic regimens, there is considerable scope for
standardisation across European centres for the diagnosis and treatment of CAP.
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Community-acquired pneumonia (CAP) is a common
cause of childhood morbidity and mortality worldwide
[1]. In North America and Europe, the annual incidence
of CAP was estimated to be approximately 34–40 cases
per 1000 in children under 5 years of age [2], prior to
widespread use of pneumococcal conjugate vaccines
(PCVs). There are several major difficulties in the diag-
nosis and treatment of CAP in children. First, the case
definitions for pneumonia are not standardised and can
vary by region and even by hospital. The diagnosis of
pneumonia is usually based on a patient’s history, clinical
signs, and laboratory test results, such as complete blood
count (CBC) and chest radiograph [3]. The World Health
Organization (WHO) has defined pneumonia entirely
based on clinical findings obtained by simple observations
[4, 5], although the specificity and sensitivity of clinical
signs for identifying pneumonia are relatively low [5–7].
Second, determining the aetiologic agent of pneumonia in
children is problematic because there is no accepted "gold
standard". Blood cultures have low sensitivity and lung
puncture is not performed routinely [3]. The distribution
of causative agents of CAP varies with age, and respiratory
virus infections are more common in early childhood
[1, 8]. Streptococcus pneumoniae is a major bacterial
cause in all age groups after the neonatal period and is
often associated with complications [9, 10]. Further-
more, co-infection with both bacteria and virus can be
found mainly in the first years of life in approximately
30 % of all cases [1, 8–10]. Third, antibiotic resistance
patterns and vaccine use differ across Europe, making it
difficult to adopt one guideline for the whole continent
[11, 12]. Recently, new guidelines from the United
States (US) [1] and the United Kingdom (UK) [13] were
published with specific recommendations regarding the
diagnosis and treatment of CAP in children.
The aims of this study were to determine whether
local guidelines for the diagnosis and treatment of CAP
in children are available in European countries; to
compare these guidelines and practices with regard to
diagnosis and treatment; and to compare these local
guidelines with published guidelines from the Pediatric
Infectious Diseases Society and the Infectious Diseases
Society of America (PIDS-IDSA) [13], the British Thoracic
Society (BTS) [1], and the WHO [15].
Methods
Study design, setting and participants
This was a snapshot prospective study based on a ques-
tionnaire sent to paediatricians and paediatric infec-
tious disease specialists across Europe from October
2010 to December 2012. The study was conducted by
the Community-Acquired Pneumonia Paediatric Re-
search Initiative (CAP-PRI) working group. CAP-PRIis a consortium convened under the auspices of the
European Society of Paediatric Infectious Diseases (ESPID),
which includes eight countries across Europe (Greece,
Israel, Italy, Lithuania, Portugal, Romania, Spain, and UK).
In each country at least one major paediatric hospital or
service is included in the consortium.
The questionnaire was emailed by the Lithuanian
group to 22 medical centres in 20 European countries.
The selection of the centres was based on the CAP-PRI
working group and other centres across Europe that
responded to an email request sent to their center and
were interested in participating in the study.
Development of the questionnaire
An original questionnaire was developed by the mem-
bers of CAP-PRI (Additional file 1); it was based on
previous published guidelines [1, 13, 14] and previous
publications on the diagnosis and treatment of CAP in
children [9, 15]. It consisted of 14 questions covering
the following 5 sections: (i) a general section describing
the use of guidelines at the centres including local or
international recommendations; (ii) use of clinical cri-
teria for the diagnosis of pneumonia (cough, fever,
tachypnoea, intercostal/subcostal/suprasternal retractions,
nasal flaring, crackles, decreased breath sounds, hypox-
aemia/oxygen saturation <95 %, dehydration, abdominal
pain, consolidation in chest radiograph); (iii) use of diagnos-
tic criteria such as chest radiograph and specific laboratory
tests (CBC, C-reactive protein [CRP], erythrocyte sedi-
mentation rate [ESR], procalcitonin [PCT], serum elec-
trolytes, blood culture, nasopharyngeal culture, sputum
culture, rapid diagnostic tests [respiratory syncytial
virus, adenovirus, human metapneumovirus], serology)
for the diagnosis of pneumonia; (iv) criteria for hospi-
talisation such as age, hypoxaemia, moderate to severe
respiratory distress, underlying disease, dehydration,
inability to feed, treatment failure, and inadequate fam-
ily supervision (v) antibiotic treatment, including local
recommendations for first and second lines of treat-
ment and the variations by age and location (both
outpatient and hospitalised inpatient).
The questionnaire was drafted in Lithuania and was
then circulated among the CAP-PRI group members
and modified according to the suggestions received.
Questionnaires were not validated as there were no
subjective questions, and we requested the hospitals to
respond based on their local guidelines and policy rather
than the opinions of the individual completing the
questionnaire.
Data collection
Questionnaire data were submitted to and recorded by
the Lithuanian group using Access Microsoft Office
2010 software (US). Every effort was made to re-contact
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responses or inconsistencies. Data was then passed to
the FISABIO-Public Health, (CSISP) group in Valencia,
Spain, for validation and statistical analysis.
Statistics
Statistical analysis was conducted by the Spanish group
using SPSS 18.0 software (SPSS Inc., US). Contingency
table analysis measured the association among centres
using the two tails χ2 tests or Fisher’s exact test. More
than one answer was possible in most of the questions.
Results
Nineteen (86.3 %) public or teaching university hospital
medical centres returned the questionnaires from 16
(80.0 %) countries: Lithuania, Latvia, Estonia, Belarus,
Israel, Spain (n = 2), Italy, Romania, Greece (n = 3),
Croatia, Portugal, Bulgaria, Slovenia, Ukraine, Slovak
Republic, and UK. All 19 centres (16 responding coun-
tries) reported to have locally available CAP guidelines.
Three out of 19 (15.8 %) responding centres use WHO
guidelines, 5 (26.3 %) centres use national guidelines, 5
(26.3 %) use guidelines approved by their hospital, 3
(15.8 %) centres use WHO and national guidelines, 2
(10.5 %) use other guidelines and 1 (5.3 %) centre did not
use paediatric CAP guidelines (Fig. 1).
Criteria for the diagnosis of CAP
Consolidation in chest radiograph was the diagnostic
criteria for CAP at all centres, and for 2 centres it was
the only requirement (Fig. 2a). At another centre, the
presence of fever and decreased air entry was also re-
quired in addition to the chest radiograph finding. The
most commonly used signs were fever (17 [89.5 %]),
decreased breath sounds (17 [89.5 %]), tachypnoea (16Fig. 1 International, national, and local guidelines usage for diagnosis and
medical centres. WHO, World Health Organization; CAP, community-acquire[84.2 %]), and crackles (16 [84.2 %]). While these clinical
signs along with chest radiographs (19 [100 %]) were
the major diagnostic criteria for CAP in centres across
Europe, others were widely used: intercostal and sub-
costal retractions (15 [79.0 %]), cough and oxygen satur-
ation <95 % (14 [73.7 %]), and nasal flaring (13 [68.4 %])
(Fig. 2a). Abdominal pain and dehydration as diagnostic
criteria were used in 62.3 % (n = 12) and 26.3 % (n = 5) of
centres, respectively, that completed the questionnaire.
Rapid respiratory rate (above the upper normal limit
for age) and chest recession were considered criteria for
diagnosis in all three guidelines (PIDS-IDSA [13], BTS
[1], and WHO [14]) (Table 1). WHO and PIDS-IDSA
guidelines also included grunting, nasal flaring, and
oxygen saturation of less than 90 %. Additionally,
PIDS-IDSA guidelines considered altered mental status
as a criterion for diagnosis and WHO considered gen-
eral danger signs such as lethargy as clinical signs and
symptoms to determine CAP. In the BTS guidelines,
temperature above 38.5 °C was a criterion for bacterial
pneumonia, while in other guidelines temperature was
not used as a criterion. Only WHO guidelines deter-
mined severity of CAP based on signs and symptoms.
Indication to obtain a chest radiograph
In all European centres chest radiograph was a criterion
for the diagnosis of pneumonia when performed. All
centres recommended chest radiograph for children
admitted to the hospital emergency room or hospita-
lised children. While 13 (68.4 %) centres performed a
chest radiograph when pneumonia was suspected, 4
(21.1 %) centres requested it only when hospitalisa-
tion was required, and 2 (10.5 %) centres requested it
when treatment failed or when a complication of
pneumonia was suspected. Eleven (57.9 %) of thetreatment of community-acquired pneumonia in children in European
d pneumonia
Fig. 2 Percentage of European medical centres that use the specified clinical and laboratory diagnostic parameters for community-acquired
pneumonia in children in European medical centres. a Clinical parameters b Laboratory tests. *Includes Mycoplasma and Chlamydia for serology and
respiratory syncytial virus, adenovirus, and influenza virus for viral diagnostic tests
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including children less than 5 years of age with fever
without focus.
Although it varied from center to center whether
WHO guidelines or other guidelines for the diagnosis of
CAP in children were used, no significant variations in
the indication for chest radiograph were found between
the groups. However, indication for chest radiograph
was related to whether the guidelines were applied in a
hospital or in the community. Thus, in the case of the 6
medical centres applying the guidelines in an outpatient
setting, chest radiograph was less frequently indicated
when CAP was suspected (33 % vs 85 %; p < 0.05), or
when findings were ambiguous (0 % vs 50 %; p < 0.05).
Although not recommended routinely by the guidelines
used in European centres, some responding centres per-
formed follow-up chest radiograph when there was an
indication. The most common indications were pleural
effusion requiring drainage in 17 (89.5 %) centres, per-
sistence of clinical symptoms after treatment with an ad-
equate antibacterial drug in 16 (84.2 %) centres, and
lung abscess in 16 (84.2 %) centres.
In all guidelines chest radiograph was not a necessary
condition for the diagnosis of CAP in children inoutpatient settings. For hospitalised patients all guide-
lines stated that chest radiograph should be performed.
The PIDS-IDSA guidelines state that “chest radiographs,
postero-anterior and lateral, should be obtained,” [13]
while the BTS guidelines state that “a lateral X-ray
should not be performed routinely” [1]. The WHO
guidelines [15] recommends a chest radiograph when
possible in all severe cases of pneumonia. Follow-up ra-
diographs were recommended in the PIDS-IDSA and
BTS guidelines only in cases of complicated pneumonia
(i.e., pleuropneumonia or lung abscess) or in non-
responsive cases.
Laboratory diagnostics
All centres performed a CBC while 16 (84.2 %) tested
for different inflammatory markers such as CRP in hos-
pitalised patients (Fig. 2b). Other diagnostic methods
frequently used were blood culture (16 [84.2 %]), ser-
ology for various respiratory pathogens (9 [47.4 %]), and
rapid viral diagnostic tests (8 [42.1 %]).
None of the guidelines recommend routine laboratory
tests for outpatients. For hospitalised patients, CBC,
ESR, PCT and CRP are recommended by the PIDS-
IDSA guidelines but not by the BTS guidelines (Table 2),
Table 1 Comparison of clinical signs and symptoms to
determine community-acquired pneumonia (CAP) severity
among different European medical centres compared with the
United States [13], United Kingdom [1] and World Health
Organization [14] guidelines
Sign or symptom Guidelines European
studyaPIDS-IDSA BTSb WHO
Tachypnoea ✓c ✓ ✓c ✓
Chest recession/indrawing/
retractions
✓ ✓ ✓ ✓
Nasal flaring ✓ ✓
Cough ✓d ✓
Grunting ✓ ✓d
Apnoea ✓
Fever ✓ ✓
Difficulty breathing/respiratory
distress
✓ ✓d ✓
Low oxygen saturation ✓
(<90 %)
✓
(<92 %)
✓d
(<90 %)
✓
(<95 %)
Abdominal pain ✓
General danger signs (inability
to drink, vomiting, lethargy,
convulsions)
✓d
Altered mental status ✓
Cyanosis ✓d
Auscultation revealing absent
breath sounds with a dull
percussion note or crackles
✓ ✓ ✓
PIDS-IDSA Pediatric Infectious Diseases Society and the Infectious Diseases
Society of America, BTS British Thoracic Society, WHO World Health
Organization
aIndications for hospitalisation, only when >50 % of medical centres reported
using the parameter
bRecommendations for bacterial pneumonia
cRespiratory rate adjusted by age
dSymptom of severe CAP
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dren with severe or complicated CAP. In severe cases,
all guidelines (except the WHO guidelines) recommended
CBC, blood cultures, and viral studies (by polymerase
chain reaction, antigen detection or serology). Several
centres reported using mycoplasma serology as well.
Pneumococcal urine antigen test is not recommended by
any guidelines for CAP in children.Criteria for hospitalisation
Recommended criteria for hospitalisation were similar
among all of the responders in all centres. The indica-
tions for hospitalisations were hypoxaemia (oxygen sat-
uration <92 %, cyanosis), moderate to severe respiratory
distress, dehydration, inability to feed, and inability of
the family to provide appropriate observation or supervi-
sion. In most centres, underlying conditions, outpatientantibiotic treatment failure, or young age (<6 months)
were also indications for hospitalisation.
In the PIDS-IDSA guidelines, children and infants
with moderate to severe CAP (respiratory distress and
hypoxaemia), infants less than 3–6 months with sus-
pected bacterial CAP, or children with CAP caused by a
pathogen with increased virulence should be hospita-
lised. In the BTS guidelines children who have oxygen
saturations <92 % or have auscultation revealing absent
breath sounds with a dull percussion note should be
referred to hospital for assessment and management. In
the WHO guidelines, any child that has a cough or
difficult breathing with chest indrawing or stridor should
urgently be referred to the hospital. In addition, the
WHO guidelines add that any child with an oxygen sat-
uration <90 % or central cyanosis should be admitted to
the hospital.
Treatment of CAP
Antibacterial treatment for CAP varied across participat-
ing centres. In all 19 centres in hospitalised patients, the
first-line treatment included either a penicillin or amino-
penicillin (Fig. 3a). Amoxicillin was used as a first-line
treatment in 7 centres; however, penicillin, ampicillin, or
cefuroxime were also recommended as a parenteral
treatment. In 11 of 19 (57.9 %) centres, a macrolide was
also recommended as a first-line treatment. As a second-
line treatment either amoxicillin/clavulanate or a second
or third generation cephalosporin was most often recom-
mended for hospitalised children (Fig. 3b). Most (84.2 %)
centres used amoxicillin as a first-line antibiotic treatment
in outpatients (Fig. 3c). Clarithromycin was also rec-
ommended as first-line or an additional treatment in
9 (47.4 %) centres, and azithromycin in 7 (36.8 %)
centres. As a second-line antibiotic treatment in out-
patients, cefuroxime or amoxicillin/clavulanate were mostly
recommended in centres, 9 (47.4 %) and 6 (32 %) respect-
ively (Fig. 3d). In cases of penicillin allergy, macrolides were
recommended.
In 17 (89.5 %) centres, treatment was related to age
(data not shown). Amoxicillin was usually recommended
as the first choice treatment for oral antibiotic therapy
in all age groups. In ambulatory children older than
5 years, amoxicillin with or without macrolides was
recommended in more than 50 % of the centres for
first-line treatment. For hospitalised patients older
than 5 years, macrolides either as a single treatment
or in combination with benzyl penicillin or cefotax-
ime were recommended.
Amoxicillin is recommended as the drug of choice for
outpatient treatment in all guidelines (Table 3). The
WHO guidelines recommend only amoxicillin for less
severe pneumonia, ampicillin and gentamicin for more
severe inpatient cases. The BTS guidelines recommend
Fig. 3 Percentage of European medical centres that use various specified antibiotics for outpatient and inpatient treatment of community acquired
pneumonia in children in European medical centres. a Inpatient first-line treatment b Inpatient second-line treatment c Outpatient first-line treatment.
d Outpatient second-line treatment. Please note that some participating medical centres use more than one antibiotic
Table 2 Comparison of inpatient diagnostic test indications for community-acquired pneumonia (CAP) across different European
medical centres compared with United States [13] and United Kingdom [1] guidelines
Diagnostic test Guideline European
studyPIDS-IDSA BTS
Chest radiograph Yes Yes Yes
Complete blood count Yesa No Yes
Acute phase reactants (CRP, serum
PCT, ESR)
Yesa,b No Yes
Sputum samples for bacteria Yes Not specified Yesc
Tests for Mycoplasma, Chlamydiad Yes Yes Yesc
Tests for respiratory virusesd Yes Yes Yesc
Blood culture Yes Yes Yes
Nasopharyngeal secretions Not specified Yes Yesc
Serum electrolytes Not specified Not specified Yes
Not recommended Urinary antigen detection for pneumococcus
Diagnostic testing for Chlamydophila pneumoniae
Urinary Antigen detection for pneumococcus
Acute phase reactants
Other Tracheal aspirates for gram stain and culture Pleural fluid for microscopy, culture and antigen
detection
With the exception of a chest radiograph, the World Health Organization does not mention use of specific inpatient diagnostic testing and is excluded from
the table
PIDS-IDSA Pediatric Infectious Diseases Society and the Infectious Diseases Society of America, BTS British Thoracic Society, ESR erythrocyte sedimentation rate,
CRP C-reactive protein, PCT procalcitonin
aDiagnostic test recommended only for those with severe disease
bAcute phase reactants cannot be used as the sole determinant to distinguish between viral and bacterial causes of CAP
cTests recommended in <50 % of medical centres
dSerology, polymerase chain reaction, culturing and other tests are available but no specific test is recommended
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Table 3 Comparison of antimicrobial empiric therapy recommendations for children with community-acquired pneumonia across
different European medical centres compared with the United States [13], United Kingdom [1] and World Health Organization [14]
guidelines
Site of care Empiric therapy
Guideline European studya
PIDS-IDSA BTS WHO
Outpatient
First-Line Amoxicillin Amoxicillin Amoxicillin Amoxicillin
Clarithromycin
Azithromycin
Second Line Macrolidesb
Azithromycin
Clarithromycin
Erythromycin
Macrolidesc
Erythromycin
Azithromycin
Clarithromycin
Co-amoxiclavd
Cefaclor
Ceftriaxone
Not Specified Cefuroxime
Amoxicillin/Clavulanic ac.
Inpatient
First-line Ampicillin
Penicillin G
Amoxicillin Ampicillin (or benzylpenicillin)
and Gentamicin
Amoxicillin
Ampicillin
Benzyl penicillin
Azithromycin
Second-Line Cephalosporine
ß-lactamc
Vancomycin or
Clindomycinf
Macrolidesc
Co-amoxiclav
Cefuroxime
Cefotaxime
Ceftriaxone
Gentamicin
Cloxacillin
Ceftriaxone
Amoxicillin/Clavulanic ac.
Cefotaxime
PIDS-IDSA Pediatric Infectious Diseases Society and the Infectious Diseases Society of America, BTS British Thoracic Society, WHO World Health Organization
aOnly drugs recommended in >30 % of the medical centres are shown, none of these drugs were recommended in >50 % of medical centres
bFor atypical pathogens, preferred and alternative agents for specific pathogens are extensively listed in [4]
cFor children in whom Mycoplasma pneumoniae and Chlamydophila pneumoniae are significant considerations
dFor pneumonia associated with influenza
eFor hospitalised infants and children who are not fully immunised
fIn addition to ß-lactam therapy if Staphylococcus aureus suspected
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nia. When intravenous (IV) treatment was mentioned
it included in the first-line antibiotic treatment amoxicillin/
clavulanate, cefuroxime and cefotaxime or ceftriaxone. In
cases when pneumonia is associated with influenza, co-
amoxicillin/clavulanate is recommended. Macrolides are
recommended in children older than 5 years by the
PIDS-IDSA and BTS guidelines in cases when atypical
pneumonia is suspected.
The second-line treatment recommendations are widely
variable and depend on age and immunisation status
(PIDS-IDSA guidelines) (Table 3). Macrolides are mostly
recommended as a single drug or in combination with ß-
lactam antibiotic. For hospitalised patients, ampicillin and
penicillin G are recommended by all guidelines. However,
for unimmunised patients, third generation cephalospo-
rins are recommended by the PIDS-IDSA guidelines. In
addition, it is recommended in the PIDS-IDSA guidelines
that vancomycin or clindamycin be used in cases caused
by Staphylococcus aureus infections and levofloxacin for
children who have reached growth maturity, or who
cannot tolerate macrolides.Discussion and conclusions
This survey reveals the great variety of clinical and labora-
tory criteria used in the diagnosis and treatment of CAP
in children within Europe. Although no standardised
guidelines for CAP in children have been established for
all of Europe, according to this study European centres
do tend to adopt guidelines, most commonly, nationally
recognised guidelines, hospital specific guidelines, or
guidelines adapted from the WHO. Chest radiograph
examination, CBC, and CRP are the most common
diagnostic criteria in the European clinics, while evalu-
ation of clinical symptoms and other laboratory tests
vary significantly. Antibiotics used for treatment in
outpatient settings such as amoxicillin and macrolides
were more uniformly used across centres; however,
antibiotic treatment varied widely in hospital settings.
Despite the heterogeneity in diagnostic practices seen
within European centres, some general similarities exist
when comparing local European practices to BTS [1],
PIDS-IDSA [13], and WHO [14] guidelines. In the
majority of European centres and in the BTS and the
PIDS-IDSA guidelines, chest radiograph was always
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pected, but was not necessary in an outpatient setting.
The WHO recommends performing a chest radiograph, if
possible, mainly for identification of complicated pneumo-
nia. Regarding laboratory diagnostics for CAP, European
guidelines and practice are most similar to PIDS-IDSA
guidelines. Both use laboratory diagnostics such as CBC,
acute phase reactants, and blood culture. No diagnostic
laboratory tests are indicated in the WHO guidelines. The
BTS guidelines are unique in advising against acute phase
reactants and do not mention CBC. The BTS guidelines
reason that acute phase reactants are not of clinical utility
in distinguishing viral from bacterial infections. A distin-
guishing factor of the PIDS-IDSA guidelines from the
European centers and WHO and BTS guidelines regard-
ing diagnosis is that the PIDS-IDSA guidelines emphasise
the importance of distinguishing viral from bacterial pneu-
monia and recommend use of sensitive and specific tests
for rapid diagnosis of viral disease. In addition, PIDS-
IDSA guidelines strongly recommend use of the influenza
virus test since it may decrease both the need for add-
itional diagnostic studies and antibiotic use.
In comparing European center practices to guidelines
for outpatient treatment of CAP, it is seen that amoxi-
cillin is consistently used and recommended as the
first-line antibiotic therapy. Use of a narrow-spectrum
antibiotics such as penicillins or aminopenicillin as a
standard of treatment is important since it will decrease
future antibiotic resistance rates. Second-line antibiotic
usage in European centres is consistent with the PIDS-
IDSA and BTS guidelines, suggesting the use of macro-
lides (although which type of macrolide varies). Although
inpatient treatment was widely variable, first-line treat-
ment in European centres was most consistent with
PIDS-IDSA guidelines with use of ampicillin as a first-
line antibiotic. Additionally, fairly rapid changes in the
inpatient management of CAP in the last 15–20 years
include a shift from routine IV to oral therapy [1, 8].
PIDS-IDSA guidelines also emphasise the importance
of pairing treatment to the specific pathogen causing the
pneumonia and extensively list specific antibiotics for
atypical pneumonia, while the BTS and WHO guide-
lines, for the most part, do not distinguish different anti-
biotics by pathogen. However, the WHO guidelines
specify that a child with a confirmed case of staphylo-
coccal pneumonia should be treated with cloxacillin and
gentamicin. Pathogen-specific antibiotic treatment in the
PIDS-IDSA guidelines probably results directly from the
recommendation for laboratory tests which identify the
pathogen at diagnosis in an effort to prevent antibiotic
resistance. Unlike other guidelines, PIDS-IDSA guide-
lines also advise more specific antibiotic treatment for
older children. For children over the age of 5 years
with presumed atypical pneumonia, macrolides can beprescribed in addition to amoxicillin, doxycycline can
be prescribed for children over 7 years of age, and
levofloxacin can be prescribed for children who have
reached growth maturity or who cannot tolerate macro-
lides. Despite such specific recommendations, compliance
with the PIDS-IDSA guidelines remains somewhat low
probably due to potential barriers to guideline adherence
including lack of guideline awareness, clinician attitudes
towards standardisation, lack of agreement with recom-
mendations, and inertia of previous practice [15].
Since there are few randomised studies—especially in
the developing world—about duration of antimicrobial
treatment, recommendations about scheduled treatment
vary between centres and guidelines. Antibiotic treat-
ment is recommended for a duration of 10 days in the
PIDS-IDSA guidelines, while the WHO recommends
treatment for 5 days and the BTS guidelines do not
specify duration of treatment. In all guidelines the dos-
age of amoxicillin antibiotic was similar (80–90 mg/day).
More studies should be performed to elucidate optimal
duration of antibiotic treatment for CAP [18].
All guidelines acknowledge that aetiology of pneumo-
nia can be influenced by age. The PIDS-IDSA guidelines
state that antimicrobial therapy is not routinely required
for preschool-aged children with CAP, because viral
pathogens are responsible for the great majority of clin-
ical disease. The BTS guidelines indicate that children
under 2 years old with mild symptoms do not usually
have bacterial pneumonia and should not be treated with
antibiotic. The WHO points out that unless the child
has clear signs of moderate to severe pneumonia, the
patient is unlikely to have bacterial pneumonia and
should not be given antibiotics. Rather, a trial of rapid
acting inhaled bronchodilator should be started and only
if no improvement is observed, antibiotic treatment can
be considered. Various studies show that viral and bac-
terial infection co-existence is prevalent [16, 17] and
thus antibiotics should be considered even in cases with
symptoms consistent with viral infections. Viral and
bacterial co-infection were not addressed in any of the
guidelines and should be addressed in future manage-
ment recommendations.
During the last 20 years, Haemophilus influenzae type
b (Hib) and pneumococcal vaccines were implemented
in many countries. These two pathogens were respon-
sible for much severe bacterial disease in children
[19, 20]. In countries that implemented these vaccines
(mainly after the introduction of PCV) a significant reduc-
tion in pneumonia rates were reported as well as in anti-
biotic resistance to pneumococcus [21, 22]. However, only
the PIDS-IDSA guidelines make a distinction between
antibiotics that should be administered to immunised ver-
sus non-immunised children. The guidelines also recom-
mend that children be immunised with vaccines against
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pertussis to prevent CAP. The BTS guidelines acknow-
ledge that vaccination has had a major impact on pneu-
monia and child mortality worldwide and that PCVs have
led to an approximate 30 % decrease in radiologically
confirmed pneumonia episodes in young children [1]. The
WHO also recommends that all routine childhood im-
munisation programs include vaccines protecting against
influenza virus, measles, pertussis, Hib, and pneumococ-
cus [23]. Despite the rise in the use of vaccines, antibiotic
resistance continues to constitute a significant problem. S.
pneumoniae still has high rates of antibiotic resistance in
various regions worldwide including Europe [24, 25, 26].
Although the survey attempts to display the current
status of diagnosis and treatment of children with CAP
in Europe, it has some limitations. First, most of the
participating countries come from southern and eastern
Europe, while northern European countries are under-
represented. Additionally, only one to two centres were
surveyed per country and almost all centres surveyed
were large academic centres, and thus the data collected
may not accurately reflect guideline use in other paediat-
ric practices and departments. Results are also based on
a self-reported questionnaire, and may not accurately
reflect the actual diagnostic and treatment methods
practiced in the clinic. It is also impossible to know if
the PIDS-IDSA, BTS, and WHO guidelines in their
respective countries or regions reflect actual practice in
the clinics without investigating within the clinics them-
selves [15]. Despite these limitations, this study does
survey clinics from diverse countries (16 different coun-
tries) and the PIDS-IDSA, BTS, and WHO guidelines
used for comparison are widely accepted and used in
their respective areas.
It is difficult to establish a uniform definition and
approach to the treatment of paediatric CAP in Europe
due to the absence of a paediatric CAP severity score,
the difficulty of identifying the aetiology, and differences
in antibiotic resistance rates. Information concerning the
changes in CAP epidemiology following the introduction
of new vaccines against respiratory pathogens is also
lacking [27]. Taking into account these difficulties, our
survey managed to reveal the great variety of clinical
and laboratory criteria used in the diagnosis and treat-
ment of CAP. Heterogeneity between centers may reflect
differences in epidemiology, aetiology, financial dispar-
ities and, in particular, vaccine usage, rate of disease and
antibiotic resistance rates. While local treatment guide-
lines are likely to vary based on local resistance patterns,
amoxicillin is suitable for most cases (especially out-
patient) in most locations. Therefore, it can be concluded
that although for diagnosis and treatment of CAP local
variations in clinical criteria, laboratory tests, and anti-
biotic resistance rates may necessitate some differencesin standard empirical antibiotic regimens, there is consid-
erable scope for standardisation across European centres.
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